Healthways Reports First-Quarter Financial Results

Revenues Increased Year-over-Year by 7% to $177 Million
Major New Contract with Fortune 100 Company among 20 Signed in First Quarter
Affirms Financial Guidance for 2014, Excluding Previously Announced Settlement Charge

Ben R. Leedle, Jr., president and chief executive officer of Healthways (HWAY), today announced financial results for the first quarter ended March 31, 2014.

  • Total revenues for the quarter were $176.8 million, up 7.0% from $165.2 million for the first quarter of 2013.
  • Net loss for the first quarter of 2014 was $9.6 million, or $0.27 per share. Adjusted net loss was $2.6 million, or $0.07 per share for the first quarter of 2014, improved from $3.9 million, or $0.12 per share, for the same period last year. (See pages 10 and 11 for a reconciliation of non-GAAP financial measures.)
Read more: Healthways ( HWAY )

WebMD Provides First Quarter Update; Expects Results To Be Above High End Of Guidance

April 14, 2014 - WebMD Health Corp. (WBMD), the leading source of health information, today announced that it expects first quarter results to exceed its previously provided financial guidance. WebMD also updated its full year 2014 guidance. WebMD's financial guidance was previously provided on February 20, 2014.

For the first quarter of 2014, WebMD expects:

  • Revenue to be at the high end of the range previously provided;
  • Earnings before interest, taxes, non-cash and other items ("Adjusted EBITDA") and net income to be slightly above the high end of the range. 

For the full year 2014, WebMD expects to be in the top half of the ranges previously provided for revenue, Adjusted EBITDA and net income.

Read more: WebMD Health Corp ( WBMD )

iKang Announces Pricing of Initial Public Offering

iKang Healthcare Group, Inc. ("iKang" or the "Company") (KANG) today announced the pricing of its initial public offering of 10,904,846 American Depositary Shares ("ADSs") at an offering price of $14 per ADS. Two ADSs represent one Class A common share. The Company's ADSs are expected to begin trading on NASDAQ on Apr. 9, 2014 (US Eastern Time) under the ticker symbol "KANG." iKang's initial public offering consists of 7,574,446 ADSs offered by iKang, and 3,330,400 ADSs offered by the selling shareholders. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 1,635,726 ADSs, all of which will be from iKang.

Read more: iKang Healthcare Group

Providence Service Corporation Agrees to Acquire Ingeus Limited

The Providence Service Corporation (PRSC), a leader in the management and provision of human social services and non-emergency transportation through a variety of government-sponsored programs, announced today that it has entered into an agreement to acquire Ingeus Limited.  Australia-based Ingeus has operations in 10 countries and four continents and is recognized as a pre-eminent distributed workforce development company and market leader in outsourced employability programs, operating in the social impr

ovement, employment and welfare services markets.  The acquisition expands Providence's footprint into new markets, diversifies its customer base, and enhances its workforce development expertise.

Read more: The Providence Service Corporation ( PRSC )

Sterigenics Enters into Definitive Agreement to Acquire Nordion

  • Transaction successfully completes Nordion’s strategic review, subject to closing, delivering value to shareholders

  • Shareholders to receive an aggregate cash consideration of US $11.75 per share

  • Nordion to hold conference call and webcast at 8:00 am ET on Monday, March 31, 2014 to discuss the announcement

Nordion Inc. (NDN.TO) (NDZ), a leading provider of products and services to the global health science market, announced that it has entered into a definitive agreement (the "Arrangement Agreement") to be acquired by Sterigenics, a global leader in sterilization services and a portfolio company of GTCR LLC, a leading private equity firm based in Chicago, Illinois, USA. Pursuant to this Arrangement Agreement, shareholders will receive an aggregate cash consideration of US$11.75 per share (collectively, the "Consideration"). Upon closing of this transaction, Nordion will operate as a standalone company within Sterigenics and will continue to operate under the Nordion name.

Read more: Nordion Inc ( NDN / NDZ )